Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

B. Falini, L. Flenghi, F. Aversa, G. Barbabietola, M. F. Martelli, P. Comeli, P. L. Tazzari, M. K. Broe, H. Stein, H. Dürkop, G. Pizzolo, A. Bolognesi, F. Stirpe, E. Sabattini, S. Pileri

Research output: Contribution to journalArticle

Abstract

In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0·8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to >75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.

Original languageEnglish
Pages (from-to)1195-1196
Number of pages2
JournalLancet
Volume339
Issue number8803
DOIs
Publication statusPublished - May 16 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin'. Together they form a unique fingerprint.

  • Cite this

    Falini, B., Flenghi, L., Aversa, F., Barbabietola, G., Martelli, M. F., Comeli, P., Tazzari, P. L., Broe, M. K., Stein, H., Dürkop, H., Pizzolo, G., Bolognesi, A., Stirpe, F., Sabattini, E., & Pileri, S. (1992). Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet, 339(8803), 1195-1196. https://doi.org/10.1016/0140-6736(92)91135-U